Trulieve Cannabis (NYSE:TRLV) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Trulieve Cannabis (NYSE:TRLV) in a research note published on Monday morning, Marketbeat.com reports. The firm issued an overweight rating and a $15.00 price objective on the stock.

Several other brokerages have also weighed in on TRLV. Wall Street Zen lowered Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Zacks Research raised shares of Trulieve Cannabis to a “hold” rating in a report on Thursday, June 18th. Finally, Weiss Ratings began coverage on shares of Trulieve Cannabis in a research report on Tuesday, June 16th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $15.00.

Trulieve Cannabis Price Performance

TRLV opened at $8.63 on Monday. Trulieve Cannabis has a 1-year low of $4.19 and a 1-year high of $13.28.

Insider Buying and Selling at Trulieve Cannabis

In related news, CEO Kim A. Rivers sold 136,811 shares of Trulieve Cannabis stock in a transaction on Friday, June 26th. The stock was sold at an average price of $8.76, for a total value of $1,198,464.36. Following the transaction, the chief executive officer directly owned 1,476,913 shares in the company, valued at $12,937,757.88. The trade was a 8.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,699,007 shares of company stock worth $14,661,355. Company insiders own 3.79% of the company’s stock.

Trulieve Cannabis Company Profile

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.